Geode Capital Management
NBSE

Geode Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Geode Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,482
Closed -$6.84K – 4675
2024
Q1 		$6.84K Hold
15,482
– – ﹤0.01% 4575
2023
Q4 		$11.5K Hold
15,482
– – ﹤0.01% 4576
2023
Q3 		$13.5K Buy
15,482
+3,786
+32% +$4.65K ﹤0.01% 4688
2023
Q2 		$21.6K Sell
11,696
-3
-0% -$10 ﹤0.01% 4650
2023
Q1 		$43.3K Hold
11,699
– – ﹤0.01% 4552
2022
Q4 		$44K Sell
11,699
-30
-0.3% -$154 ﹤0.01% 4630
2022
Q3 		$92K Hold
11,729
– – ﹤0.01% 4608
2022
Q2 		$246K Sell
11,729
-470
-4% -$11K ﹤0.01% 4140
2022
Q1 		$458K Hold
12,199
– – ﹤0.01% 3975
2021
Q4 		$685K Buy
12,199
+208
+2% +$14K ﹤0.01% 3886
2021
Q3 		$865K Buy
11,991
+298
+3% +$22.8K ﹤0.01% 3756
2021
Q2 		$1.12M Sell
11,693
-4,083
-26% -$451K ﹤0.01% 3532
2021
Q1 		$2.33M Buy
15,776
+3,079
+24% +$558K ﹤0.01% 3181
2020
Q4 		$1.77M Buy
12,697
+741
+6% +$120K ﹤0.01% 3145
2020
Q3 		$1.81M Buy
11,956
+4,332
+57% +$707K ﹤0.01% 2926
2020
Q2 		$1.34M Buy
7,624
+6,814
+841% +$1.14M ﹤0.01% 3045
2020
Q1 		$115K Hold
810
– – ﹤0.01% 3722
2019
Q4 		$116K Buy
810
+12
+2% +$1.41K ﹤0.01% 3952
2019
Q3 		$79K Hold
798
– – ﹤0.01% 3998
2019
Q2 		$54K Buy
798
+128
+19% +$7.25K ﹤0.01% 4074
2019
Q1 		$30K Hold
670
– – ﹤0.01% 4068
2018
Q4 		$23K Hold
670
– – ﹤0.01% 4083
2018
Q3 		$49K Hold
670
– – ﹤0.01% 4031
2018
Q2 		$52K Hold
670
– – ﹤0.01% 3977
2018
Q1 		$58K Buy
670
+324
+94% +$48.2K ﹤0.01% 3934
2017
Q4 		$257K Sell
346
-32
-8% -$12.4K ﹤0.01% 3593
2017
Q3 		$108K Hold
378
– – ﹤0.01% 3816
2017
Q2 		$96K Sell
378
-6
-2% -$1.61K ﹤0.01% 3853
2017
Q1 		$127K Buy
384
+1
+0.3% +$463 ﹤0.01% 3778
2016
Q4 		$229K Buy
383
+1
+0.3% +$1.06K ﹤0.01% 3574
2016
Q3 		$432K Hold
382
– – ﹤0.01% 3309
2016
Q2 		$418K Hold
382
– – ﹤0.01% 3290
2016
Q1 		$490 Buy
382
+14
+4% +$19.9K ﹤0.01% 3251
2015
Q4 		$903K Sell
368
-4
-1% -$6.14K ﹤0.01% 2961
2015
Q3 		$410K Buy
372
+89
+31% +$103K ﹤0.01% 3312
2015
Q2 		$284K Sell
283
-41
-13% -$44.2K ﹤0.01% 3448
2015
Q1 		$329K Buy
324
+42
+15% +$139K ﹤0.01% 3383
2014
Q4 		$939K Buy
282
+5
+2% +$15.3K ﹤0.01% 2885
2014
Q3 		$803K Hold
277
– – ﹤0.01% 2918
2014
Q2 		$1.05M Buy
277
+71
+34% +$267K ﹤0.01% 2768
2014
Q1 		$1.12M Buy
206
+138
+203% +$727K ﹤0.01% 2716
2013
Q4 		$214K Buy
68
+21
+45% +$64.8K ﹤0.01% 3408
2013
Q3 		$151K Buy
+47
New +$128K ﹤0.01% 3400

Other funds holding NBSE

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Geode Capital Management's NBSE Position: Q2 2024 in Review

Geode Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 15,482 shares — an estimated $6.84K sold.

Geode Capital Management first reported a position in NBSE in Q3 2013 and held it in 43 quarters. The position peaked at $2.33M in Q1 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

  • Geode Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 15,482 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $6.84K.
  • Geode Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 43 quarters.
  • Geode Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.33M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.